Currently Viewing:
Evidence-Based Oncology July 2017
Daratumumab With Standard Regimen Improves PFS, ORR Independent of Cytogenetic Risk in Multiple Myeloma
Surabhi Dangi-Garimella, PhD
Phase 1 Study Results at ASCO Support First-Line Use of Daratumumab in Multiple Myeloma
Surabhi Dangi-Garimella, PhD
Daratumumab-Based Combination Effective in Relapsed/Refractory Multiple Myeloma, Short PFS in Heavily Pretreated Patients
Surabhi Dangi-Garimella, PhD
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
Surabhi Dangi-Garimella, PhD
An Early Stage Safety, Efficacy Study for Atezolizumab Plus Daratumumab in Advanced NSCLC
Surabhi Dangi-Garimella, PhD
LDH Levels Could Predict irAEs Associated With Checkpoint Inhibition and Radiotherapy in Lung Cancer
Surabhi Dangi-Garimella, PhD
Alectinib May Be a New Standard of Care for Treatment-Naïve ALK-Positive NSCLC
AJMC Staff
Dacomitinib a New First-Line Option for Advanced EGFR Mutation—Positive NSCLC
AJMC Staff
Androgen Deprivation, With or Without Radiotherapy, New Standard of Care in High-Risk Prostate Cancer
AJMC Staff
Trabectedin and Lurbinectedin Effective in BRCA2-Associated Metastatic Breast Cancer
AJMC Staff
HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults
Surabhi Dangi-Garimella, PhD
Physical Activity, Healthy Diet Improve Survival in Colorectal Cancer: Study at ASCO
Surabhi Dangi-Garimella, PhD
Three Months of Oxaliplatin-Based Adjuvant Therapy Noninferior to 6 Months in Stage III Colon Cancer
AJMC Staff
Fas Biomarker Can Predict Response to Second-Line Therapy for Advanced Soft Tissue Sarcoma
AJMC Staff
Nivolumab, Alone or With Ipilimumab, Met the Disease Control Rate in Malignant Pleural Mesothelioma
AJMC Staff
Ibrutinib vs No Consolidation Are Being Compared Following Autologous HSCT in IRONCLAD Trial
AJMC Staff
Web-Based Patient Reporting of Symptoms Shown to Improve Survival in Patients With Metastatic Solid Tumors
AJMC Staff
Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data
Surabhi Dangi-Garimella, PhD
Do We Have Adequate Surveillance in Cancer Care?
Surabhi Dangi-Garimella, PhD
MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges
Surabhi Dangi-Garimella, PhD
ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation
Surabhi Dangi-Garimella, PhD
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
Surabhi Dangi-Garimella, PhD
Research Demonstrates Efficacy and Safety of Trastuzumab Biosimilar SB3
Kelly Davio
CT-P6, a Trastuzumab Biosimilar, Shares the Safety and Efficacy Profile of Its Reference
Kelly Davio
Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?
Surabhi Dangi-Garimella, PhD
Currently Reading
Adjuvant Chemotherapy Reduces Cost, Improves Survival in NSCLC Post-Surgery
Surabhi Dangi-Garimella, PhD
SEER-Medicare Database Analysis Notes Higher Resource Utilization Among Patients With Neuroendocrine Tumors
Surabhi Dangi-Garimella, PhD

Adjuvant Chemotherapy Reduces Cost, Improves Survival in NSCLC Post-Surgery

Surabhi Dangi-Garimella, PhD
Including adjuvant chemotherapy in the postsurgical treatment plan in patients with non—small cell lung cancer (NSCLC) improves survival and is cost-effective compared with surgical resection alone, according to analysis results presented at the 2017 American Society of Clinical Oncology Annual Meeting.
A COST-EFFECTIVENESS ANALYSIS conducted by researchers at Rush University, Washington University, and St. Louis University has found that including adjuvant chemotherapy in the postsurgical treatment plan in patients with non–small cell lung cancer (NSCLC) improves survival and is cost-effective compared with surgical resection alone. The results were presented at the 2017 American Society of Clinical Oncology Annual Meeting.

The benefits of adjuvant chemotherapy in stage I NSCLC remain controversial, as patients die from systemic relapse. Therefore, the authors of the current study evaluated the effectiveness and cost-effectiveness of adjuvant chemotherapy after surgical resection in stage IB NSCLC.

The authors conducted propensity score matching on the National Cancer Database for the period between 2004 and 2011. The Kaplan-Meier method generated conditional probabilistic incremental 1- to 5-year survival after surgical resection stratified by receipt of adjuvant chemotherapy. Medicare- allowable charges for surgical resection and adjuvant chemotherapy, and their respective complications, were used, and proportions of chemotherapeutic agents administered in real-world settings were estimated by decision modeling. The incremental cost-effectiveness ratio (ICER) was calculated over a 5-year period.

The analysis found that 3662 of 18,709 patients who met the inclusion criteria received adjuvant chemotherapy and surgical resection for stage IB NSCLC; the annual usage ranged from 15% to 27%. Propensity score matching showed an overall survival benefit of including adjuvant chemotherapy in the treatment plan over surgical resection alone (at 5 years: 68.9% vs 60.4%; P <.001).

The incremental cost of adjuvant chemotherapy over surgical resection alone was $11,541, and the incremental effectiveness of adjuvant chemotherapy was 0.28 life-years, with an ICER of $41,218. Using 2-way sensitivity analysis, the authors found that the combination treatment dominated for the entire range of cost and survival estimates, while with a probabilistic sensitivity analysis, the combination dominated the model above a willing-to-pay threshold of $16,000. While adjuvant chemotherapy costs could nearly double, the ICER remained under conventional thresholds. However, only 3 of the 4 common adjuvant chemotherapy regimens were cost-effective.

Based on their findings, the authors conclude that in stage IB NSCLC, surgery is insufficient to render a cure, but that including adjuvant chemotherapy in the treatment plan extends life expectancy and is cost-effective compared with surgery alone. These conclusions are valid over a range of clinically meaningful variations in cost and treatment outcomes, although a cost-conscious approach is needed when selecting an adjuvant chemotherapy regimen.
REFERENCE

Hudson JL, Aung WY, Santos C, et al. The role of adjuvant chemotherapy in stage IB non-small cell lung cancer: a decision, effectiveness, and cost-effectiveness analysis. J Clin Oncol. 2017;35(suppl; abstract 8526).
PDF
 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!